(4-Pack) Tirzepatide – 30mg
nothing more. nothing less.
SHIPS IN 1 BUSINESS DAY
Lightning-fast shipping · USA · tracked
For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.
Blank. Credentials
Institutional-grade credentials you can verify
About This Compound
Deep technical insights for clinical research
Primary Research Applications
This compound is supplied strictly for in-vitro and preclinical research use only. Research focuses on the modulation of cellular repair mechanisms and upregulation of specific growth factor receptors in laboratory models.
Evaluation of metabolic activity and proliferation rates in relevant cell lineages.
Investigation of intracellular signaling cascades in controlled laboratory settings.
Research Community Feedback
"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."
Dr. Julian Kessler
Lead Investigator, Biomatrix Labs
"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."
Anika S. Singh
Synthetics Quality Control
"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."
Prof. David Emmerich
Applied Peptide Research
Complete The Protocol
Pairs & Supplies
The compounds and tools researchers stack with (4-Pack) Tirzepatide - 30mg.
Peer-Reviewed Literature
Related Studies
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine
72-week landmark trial of 2,539 patients showed tirzepatide achieved body weight reductions of 15.0–20.9% versus 3.1% placebo — establishing dual GIP/GLP-1 agonism superiority.
Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes (SURPASS-2)
New England Journal of Medicine
Head-to-head trial of 1,879 patients showed tirzepatide achieved superior HbA1c reduction and greater weight loss (5.5–7.3 kg) than semaglutide 1 mg.
Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity (SURMOUNT-3)
Nature Medicine
72-week trial showed tirzepatide achieved additional 18.4% weight loss beyond intensive lifestyle intervention, with 95% reaching ≥5% total weight loss.
Efficacy and Safety of Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1)
The Lancet
40-week monotherapy trial showed tirzepatide produced superior HbA1c reduction of 1.9–2.5% and weight loss of 7.0–9.5 kg, with 92% achieving HbA1c <7%.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
New England Journal of Medicine
Head-to-head comparison showed tirzepatide 15 mg reduced HbA1c by 2.46% vs semaglutide 1 mg 1.86%, with body weight reductions of 12.4 kg vs 6.2 kg at 40 weeks in 1,879 T2D patients.
Tirzepatide Once Weekly for the Treatment of Obesity in People Without Diabetes (SURMOUNT-1)
New England Journal of Medicine
In 2,539 adults with BMI ≥30, tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks — the largest weight reduction ever achieved with a pharmaceutical agent at the time.